Related Experiment Video

Updated: Sep 1, 2025

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

1.8K

The effect of tropisetron on peripheral diabetic neuropathy: possible protective actions against inflammation and

Amir Mohammad Ghazipour1, Bagher Pourheydar2,3, Roya Naderi4,5

  • 1Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.

Cell Stress & Chaperones
|August 16, 2022
PubMed

Insights

Tropisetron shows protective effects against diabetic peripheral neuropathy (DPN). It reduces nerve damage and inflammation in diabetic rats, suggesting a potential therapeutic strategy for DPN.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic peripheral neuropathy (DPN) is a common complication of diabetes, characterized by nerve damage.
  • Existing treatments for DPN have limitations, necessitating the exploration of novel therapeutic agents.

Purpose of the Study:

  • To investigate the potential neuroprotective effects of tropisetron in a rat model of type 1 diabetes-induced peripheral neuropathy.

Main Methods:

  • Type 1 diabetes was induced using streptozotocin.
  • Tropisetron was administered daily for two weeks.
  • Nerve fiber morphology, myelination, apoptosis markers (Bax, Bcl-2), and inflammatory cytokines (TNF-α, IL-1β) were assessed.

Main Results:

  • Diabetes caused nerve fiber thinning, reduced myelinated fiber count, and increased apoptosis markers in sciatic nerves.
  • Diabetic rats exhibited elevated levels of TNF-α and IL-1β.
  • Tropisetron treatment significantly reversed these diabetes-induced pathological changes.

Conclusions:

  • Tropisetron demonstrates significant anti-inflammatory and anti-apoptotic effects in the context of diabetic peripheral neuropathy.
  • These findings suggest tropisetron as a promising therapeutic candidate for managing DPN.
Keywords:
ApoptosisDiabetesInflammationSciatic injuryTropisetron

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

498
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
309
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
275
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
426
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
239
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
254
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
570